(Total Views: 509)
Posted On: 06/29/2023 6:20:25 AM
Post# of 154867
From reading the Bio on Meidling what stands out the most?
Mr. Meidling joined CytoDyn in March of 2021 as Senior Director of Portfolio and Project Management and, in May of 2022, was appointed Senior Director of Clinical Operations. Before joining CytoDyn, Mr. Meidling spent nearly 22 years at Merck, where he held various positions of increasing responsibilities in Drug Development. He was a director in Clinical Pharmacology and Translational Medicine. He led the Pharmacogenomics and Biorepository group before moving on to become the site lead for Merck’s Kenilworth facility and was responsible for Merck’s Early-Stage Development portfolio and resource planning. Mr. Meidling has a BS in Engineering from the New Jersey Institute of Technology and an MBA from Montclair State University.
Mr. Meidling joined CytoDyn in March of 2021 as Senior Director of Portfolio and Project Management and, in May of 2022, was appointed Senior Director of Clinical Operations. Before joining CytoDyn, Mr. Meidling spent nearly 22 years at Merck, where he held various positions of increasing responsibilities in Drug Development. He was a director in Clinical Pharmacology and Translational Medicine. He led the Pharmacogenomics and Biorepository group before moving on to become the site lead for Merck’s Kenilworth facility and was responsible for Merck’s Early-Stage Development portfolio and resource planning. Mr. Meidling has a BS in Engineering from the New Jersey Institute of Technology and an MBA from Montclair State University.
(2)
(0)
